

Peter Brnnum Nielsen

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8580523/peter-bronnum-nielsen-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

78
papers

1,833
citations

22
h-index

42
g-index

92
ext. papers

2,207
ext. citations

6.3
avg, IF

5.3
L-index

#	Paper	IF	Citations
78	Validation of the Khorana score for predicting venous thromboembolism in 40 218 cancer patients initiating chemotherapy.. <i>Blood Advances</i> , 2022 ,	7.8	1
77	Risk of Cerebrovascular Events in Intracerebral Hemorrhage Survivors With Atrial Fibrillation: A Nationwide Cohort Study.. <i>Stroke</i> , 2022 , 101161STROKEAHA121038331	6.7	1
76	Thromboembolic Risk in Patients With Pneumonia and New-Onset Atrial Fibrillation Not Receiving Anticoagulation Therapy. <i>JAMA Network Open</i> , 2022 , 5, e2213945	10.4	0
75	Effectiveness and Safety of NOAC Versus Warfarin in Patients With Atrial Fibrillation and Aortic Stenosis. <i>Journal of the American Heart Association</i> , 2021 , 10, e022628	6	0
74	Intracerebral Hemorrhage and Exposure to Antithrombotic Drugs. <i>JAMA Network Open</i> , 2021 , 4, e219175	5.4	0
73	Bleeding complications in patients with gastrointestinal cancer and atrial fibrillation treated with oral anticoagulants. <i>Cancer Medicine</i> , 2021 , 10, 4405-4414	4.8	1
72	Characteristics of patients receiving extended treatment after incident venous thromboembolism. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2021 , 129, 332-342	3.1	0
71	Comparative effectiveness and safety of edoxaban versus warfarin in patients with atrial fibrillation: A nationwide cohort study. <i>International Journal of Stroke</i> , 2021 , 17474930211029441	6.3	1
70	Thromboembolism and bleeding complications in anticoagulated patients with atrial fibrillation and native aortic or mitral valvular heart disease: a descriptive nationwide cohort study. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 , 7, F101-F110	6.4	11
69	Temporal Changes in Secondary Prevention and Cardiovascular Outcomes After Revascularization for Peripheral Arterial Disease in Denmark: A Nationwide Cohort Study. <i>Circulation</i> , 2021 , 143, 907-920	16.7	3
68	Effectiveness and safety of edoxaban in patients with atrial fibrillation: data from the Danish Nationwide Cohort. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 , 7, 31-39	6.4	3
67	Should we make the risk stratification process more complex in patients with atrial fibrillation?. <i>Europace</i> , 2021 , 23, 978	3.9	1
66	Development of Sex-Stratified Prediction Models for Recurrent Venous Thromboembolism: A Danish Nationwide Cohort Study. <i>Thrombosis and Haemostasis</i> , 2020 , 120, 805-814	7	8
65	Female Sex as a Risk Modifier for Stroke Risk in Atrial Fibrillation: Using CHA2DS2-VASc versus CHA2DS2-VA for Stroke Risk Stratification in Atrial Fibrillation: A Note of Caution. <i>Thrombosis and Haemostasis</i> , 2020 , 120, 894-898	7	14
64	Thromboembolic and bleeding outcomes in patients with atrial fibrillation and valvular heart disease: A descriptive nationwide cohort study. <i>International Journal of Clinical Practice</i> , 2020 , 74, e13589	3.9	3
63	Incidence and prognostic factors for recurrence of intracerebral hemorrhage in patients with and without atrial fibrillation: A cohort study. <i>Thrombosis Research</i> , 2020 , 191, 1-8	8.2	6
62	Letter by Nielsen and Sjøgaard Regarding Article, "Rivaroxaban Versus Apixaban for Stroke Prevention in Atrial Fibrillation: An Instrumental Variable Analysis of a Nationwide Cohort". <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020 , 13, e006889	5.8	0

61	Thromboembolic Risk in Nonanticoagulated Patients With Atrial Fibrillation and Valvular Heart Disease. <i>JACC: Clinical Electrophysiology</i> , 2020 , 6, 1672-1682	4.6	
60	Correspondence: Current opinion of the ESC Working Group on Cardiovascular Pharmacotherapy and ESC Council on Stroke. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020 , 6, 265-266	6.4	1
59	Evaluation of the CHEST Risk Score as a Possible Opportunistic Screening Tool for Incident Atrial Fibrillation in a Healthy Population (From a Nationwide Danish Cohort Study). <i>American Journal of Cardiology</i> , 2020 , 125, 48-54	3	12
58	Predictors of Not Initiating Anticoagulation After Incident Venous Thromboembolism: A Danish Nationwide Cohort Study. <i>American Journal of Medicine</i> , 2020 , 133, 463-472.e5	2.4	2
57	How to optimize the value of administrative venous thromboembolism codes. <i>Thrombosis Research</i> , 2020 , 194, 195-196	8.2	
56	Cancer-associated venous thromboembolism and the non-vitamin K antagonist oral anticoagulants: a review of clinical outcomes and patient perspectives. <i>Expert Review of Cardiovascular Therapy</i> , 2020 , 18, 791-800	2.5	2
55	Albuminuria and Risk of Cardiovascular Events and Mortality in a General Population of Patients with Type 2 Diabetes Without Cardiovascular Disease: A Danish Cohort Study. <i>American Journal of Medicine</i> , 2020 , 133, e269-e279	2.4	4
54	Extended oral anticoagulation after incident venous thromboembolism - a paradigm shift?. <i>Expert Review of Cardiovascular Therapy</i> , 2020 , 18, 201-208	2.5	2
53	Glycemic Status and Thromboembolic Risk in Patients With Atrial Fibrillation and Type 2 Diabetes Mellitus: A Danish Cohort Study. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2019 , 12, e007030	6.4	30
52	Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Atrial Fibrillation Patients With Intracerebral Hemorrhage. <i>Stroke</i> , 2019 , 50, 939-946	6.7	18
51	Risk of recurrence and bleeding in patients with cancer-associated venous thromboembolism treated with rivaroxaban: A nationwide cohort study. <i>Cancer Medicine</i> , 2019 , 8, 1044-1053	4.8	9
50	Stroke risk in female patients with atrial fibrillation: Relationship to current guideline recommendations. <i>Trends in Cardiovascular Medicine</i> , 2019 , 29, 150-152	6.9	1
49	Sex differences in risk of incident venous thromboembolism in heart failure patients. <i>Clinical Research in Cardiology</i> , 2019 , 108, 101-109	6.1	10
48	Stroke and bleeding risk scores in patients with atrial fibrillation and valvular heart disease: evaluating valvular heart diseases in a nationwide cohort study. <i>Europace</i> , 2019 , 21, 33-40	3.9	20
47	Risk Stratification for Ischemic Cerebrovascular Events and Mortality among Intracerebral Hemorrhage Patients with and without Atrial Fibrillation: A Nationwide Cohort Study. <i>Cerebrovascular Diseases</i> , 2019 , 48, 236-243	3.2	4
46	Stroke Risk Stratification: CHADS-VA or CHADS-VASc?. <i>Heart Lung and Circulation</i> , 2019 , 28, e14-e15	1.8	8
45	Rivaroxaban Versus Warfarin and Risk of Post-Thrombotic Syndrome Among Patients with Venous Thromboembolism. <i>American Journal of Medicine</i> , 2018 , 131, 787-794.e4	2.4	13
44	Female Sex Is a Risk Modifier Rather Than a Risk Factor for Stroke in Atrial Fibrillation: Should We Use a CHADS-VA Score Rather Than CHADS-VASc?. <i>Circulation</i> , 2018 , 137, 832-840	16.7	93

43	The HAS-BLED, ATRIA, and ORBIT Bleeding Scores in Atrial Fibrillation Patients Using Non-Vitamin K Antagonist Oral Anticoagulants. <i>American Journal of Medicine</i> , 2018 , 131, 574.e13-574.e27	2.4	29
42	Understanding the Value of Real-World Evidence: Focus on Stroke Prevention in Atrial Fibrillation with Rivaroxaban. <i>Thrombosis and Haemostasis</i> , 2018 , 118, S45-S60	7	7
41	Restarting oral anticoagulant therapy after major bleeding in atrial fibrillation: A systematic review and meta-analysis. <i>International Journal of Cardiology</i> , 2018 , 261, 84-91	3.2	15
40	Type 1 versus type 2 diabetes and thromboembolic risk in patients with atrial fibrillation: A Danish nationwide cohort study. <i>International Journal of Cardiology</i> , 2018 , 268, 137-142	3.2	16
39	Anticoagulant treatment of cancer-associated venous thromboembolism: Interpreting real-world data with caution. <i>American Journal of Hematology</i> , 2018 , 93, E224-E225	7.1	1
38	Response by Overvad et al to Letter Regarding Article, "Female Sex Is a Risk Modifier Rather Than a Risk Factor for Stroke in Atrial Fibrillation: Should We Use a CHADS-VA Score Rather Than CHADS-VASc?". <i>Circulation</i> , 2018 , 138, 443-444	16.7	
37	Risk of Recurrent Venous Thromboembolism: A Danish Nationwide Cohort Study. <i>American Journal of Medicine</i> , 2018 , 131, 1067-1074.e4	2.4	31
36	Associations between socioeconomic status, atrial fibrillation, and outcomes: a systematic review. <i>Expert Review of Cardiovascular Therapy</i> , 2018 , 16, 857-873	2.5	12
35	Effectiveness and safety of self-managed oral anticoagulant therapy compared with direct oral anticoagulants in patients with atrial fibrillation. <i>Scientific Reports</i> , 2018 , 8, 15805	4.9	10
34	Outcomes Associated With Resuming Warfarin Treatment After Hemorrhagic Stroke or Traumatic Intracranial Hemorrhage in Patients With Atrial Fibrillation. <i>JAMA Internal Medicine</i> , 2017 , 177, 563-570	11.5	58
33	Letter by Nielsen and Johnsen Regarding Article, "Optimal Timing of Anticoagulant Treatment After Intracerebral Hemorrhage in Patients With Atrial Fibrillation". <i>Stroke</i> , 2017 , 48, e115	6.7	1
32	Effectiveness and safety of rivaroxaban and warfarin in patients with unprovoked venous thromboembolism: a propensity-matched nationwide cohort study. <i>Lancet Haematology</i> , 2017 , 4, e237-e244	14.6	29
31	Premature atrial complexes in an ischemic stroke population and risk of recurrent stroke: a systematic review. <i>Expert Review of Cardiovascular Therapy</i> , 2017 , 15, 447-455	2.5	3
30	Effectiveness and Safety of Standard-Dose Nonvitamin K Antagonist Oral Anticoagulants and Warfarin Among Patients With Atrial Fibrillation With a Single Stroke Risk Factor: A Nationwide Cohort Study. <i>JAMA Cardiology</i> , 2017 , 2, 872-881	16.2	34
29	All Types of Hemorrhagic Stroke Are Not Created Equally-Reply. <i>JAMA Internal Medicine</i> , 2017 , 177, 1399-1401	11.5	
28	Long-term antithrombotic treatment in intracranial hemorrhage survivors with atrial fibrillation. <i>Neurology</i> , 2017 , 89, 687-696	6.5	53
27	Treatment thresholds for stroke prevention in atrial fibrillation: observations on the CHA2DS2-VASc score. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2017 , 3, 37-41	6.4	22
26	Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. <i>BMJ, The</i> , 2017 , 356, j510	5.9	215

25	Response by Nielsen and Lip to Letter Regarding Article, "Should Patients With Atrial Fibrillation and 1 Stroke Risk Factor (CHA2DS2-VASc Score 1 in Men, 2 in Women) Be Anticoagulated? Yes: Even 1 Stroke Risk Factor Confers a Real Risk of Stroke". <i>Circulation</i> , 2016 , 134, e389-e390	16.7	
24	Stroke and thromboembolic event rates in atrial fibrillation according to different guideline treatment thresholds: A nationwide cohort study. <i>Scientific Reports</i> , 2016 , 6, 27410	4.9	48
23	Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. <i>BMJ, The</i> , 2016 , 353, i3189	5.9	280
22	Letter by Nielsen et al Regarding Article, "Ischemic Stroke Risk in Patients With Atrial Fibrillation and CHA2DS2-VASc Score of 1: Systematic Review and Meta-Analysis". <i>Stroke</i> , 2016 , 47, e193	6.7	
21	Response. <i>Chest</i> , 2016 , 149, 1590-1	5.3	
20	EBlockers in Atrial Fibrillation Patients With or Without Heart Failure: Association With Mortality in a Nationwide Cohort Study. <i>Circulation: Heart Failure</i> , 2016 , 9, e002597	7.6	37
19	Recalibration of the HAS-BLED Score: Should Hemorrhagic Stroke Account for One or Two Points?. <i>Chest</i> , 2016 , 149, 311-314	5.3	9
18	Self-Management of Anticoagulant Therapy in Mechanical Heart Valve Patients: A Matched Cohort Study. <i>Annals of Thoracic Surgery</i> , 2016 , 101, 1494-9	2.7	10
17	Should Patients With Atrial Fibrillation and 1 Stroke Risk Factor (CHA2DS2-VASc Score 1 in Men, 2 in Women) Be Anticoagulated? Yes: Even 1 Stroke Risk Factor Confers a Real Risk of Stroke. <i>Circulation</i> , 2016 , 133, 1498-503; discussion 1503	16.7	28
16	Misconceptions on Interpretation of Risk Prediction Tools in Atrial Fibrillation. <i>American Journal of Medicine</i> , 2016 , 129, e31	2.4	2
15	Stroke and mortality after atrial fibrillation-a global struggle. <i>Lancet, The</i> , 2016 , 388, 1131-2	40	
14	Atrial flutter and thromboembolic risk: a systematic review. <i>Heart</i> , 2015 , 101, 1446-55	5.1	41
13	Intracranial hemorrhage and subsequent ischemic stroke in patients with atrial fibrillation: a nationwide cohort study. <i>Chest</i> , 2015 , 147, 1651-1658	5.3	35
12	Renal function and non-vitamin K oral anticoagulants in comparison with warfarin on safety and efficacy outcomes in atrial fibrillation patients: a systemic review and meta-regression analysis. <i>Clinical Research in Cardiology</i> , 2015 , 104, 418-29	6.1	77
11	Composite end point analyses of non-vitamin K antagonist oral anticoagulants compared with warfarin in patients with atrial fibrillation. <i>Expert Review of Cardiovascular Therapy</i> , 2015 , 13, 1155-63	2.5	1
10	Atrial fibrillation patients categorized as "not for anticoagulation" according to the 2014 Canadian Cardiovascular Society algorithm are not "low risk". <i>Canadian Journal of Cardiology</i> , 2015 , 31, 24-8	3.8	13
9	The risks of risk scores for stroke risk assessment in atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2015 , 113, 1170-3	7	39
8	Non-valvular atrial fibrillation patients with none or one additional risk factor of the CHA2DS2-VASc score. A comprehensive net clinical benefit analysis for warfarin, aspirin, or no therapy. <i>Thrombosis and Haemostasis</i> , 2015 , 114, 826-34	7	77

7	Comparison of Atrial Fibrillation Guidelines. <i>Journal of General Internal Medicine</i> , 2015 , 30, 1404	4	
6	Restarting Anticoagulant Treatment After Intracranial Hemorrhage in Patients With Atrial Fibrillation and the Impact on Recurrent Stroke, Mortality, and Bleeding: A Nationwide Cohort Study. <i>Circulation</i> , 2015 , 132, 517-25	16.7	189
5	Improvement of anticoagulant treatment using a dynamic decision support algorithm: a Danish Cohort study. <i>Thrombosis Research</i> , 2014 , 133, 375-9	8.2	8
4	The value of the European society of cardiology guidelines for refining stroke risk stratification in patients with atrial fibrillation categorized as low risk using the anticoagulation and risk factors in atrial fibrillation stroke score: a nationwide cohort study. <i>Chest</i> , 2014 , 146, 1337-1346	5.3	29
3	Non-vitamin K antagonist oral anticoagulants and the treatment of venous thromboembolism in cancer patients: a semi systematic review and meta-analysis of safety and efficacy outcomes. <i>PLoS ONE</i> , 2014 , 9, e114445	3.7	46
2	Sex differences in treatment quality of self-managed oral anticoagulant therapy: 6,900 patient-years of follow-up. <i>PLoS ONE</i> , 2014 , 9, e113627	3.7	20
1	Monitoring of anticoagulant therapy applying a dynamic statistical model. <i>Computer Methods and Programs in Biomedicine</i> , 2013 , 110, 380-8	6.9	4